BioCentury
ARTICLE | Strategy

Allston chronicles

November 16, 2009 8:00 AM UTC

Genzyme Corp.'s manufacturing woes have depressed the stock over the last nine months. The biotech has slipped 19% since Feb. 27, the day before Genzyme (NASDAQ:GENZ) announced it received a warning l...